Form 4: Cullinan CSO Sells Shares for Tax, 10b5-1 Plan

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported sales of common stock totaling 3,143 shares across two transactions in December 2025, primarily for tax obligations and a pre-arranged trading plan.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported two sales of common stock.
• On December 12, 2025, 2,148 shares were sold at a price of $12.38 per share to cover personal income tax obligations upon the vesting of restricted stock units.
• On December 15, 2025, an additional 995 shares were sold at a price of $11.90 per share, executed pursuant to a Rule 10b5-1 trading plan established on August 7, 2025.
• Following these transactions, Jennifer Michaelson beneficially owns 136,878 shares of Cullinan Therapeutics common stock.
• The reported beneficial ownership includes 2,017 shares of common stock purchased by the Reporting Person through the Issuer's 2021 Employee Stock Purchase Plan for the period of January 1, 2025, through June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are insider sales, they are for expected reasons (tax obligations, 10b5-1 plan) and are offset by an ESPP purchase. These are routine transactions and do not suggest a negative outlook on the company's future.

Positives

• The reporting person acquired 2,017 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) for the first half of 2025, indicating continued participation in employee ownership programs.

Negatives

• The Chief Scientific Officer sold a total of 3,143 shares of common stock in December 2025, which represents a reduction in direct beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific insights into broader industry trends or competitive landscape. It reflects individual executive compensation and personal financial planning within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sales represent a minor reduction in insider ownership, but the reasons (tax, 10b5-1 plan) suggest these are routine and not indicative of a change in management's confidence. The ESPP purchase shows continued alignment.
• Employees: The ESPP participation highlights the company's employee stock ownership program, which can be a positive for employee retention and alignment.

Key Dates

Recommendation

The reported transactions are routine insider sales for tax obligations and a pre-established 10b5-1 trading plan, which are common and generally not indicative of a change in the company's fundamental prospects or management's long-term view. The concurrent ESPP purchase further supports a neutral stance. Therefore, based solely on this Form 4, a 'hold' recommendation is appropriate as it does not provide new information warranting a change in investment thesis.

Keywords

Cullinan Therapeutics, CGEM, Insider Trading, Form 4, Stock Sale, Chief Scientific Officer, Jennifer Michaelson, 10b5-1 Plan, Restricted Stock Units, ESPP